SUMMARY A double-blind crossover trial was conducted of thyrotropin releasing hormone treatment in six patients with amyotrophic lateral sclerosis. Patients received 4 mg of thyrotropin releasing hormone intramuscularly daily during the two-week treatment period. Although three patients reported subjective improvement, objective evaluation failed to demonstrate therapeutic effectiveness of thyrotropin releasing hormone in this dosage. 
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Based on evidence that thyrotropin releasing hormone (TRH) may be a trophic factor or transmitter of motor neurons, ' -4 Engel et al gave thyrotropin releasing hormone in a massive dose (200 mg) Results are mean + SD. n = number of patients. In 11 subtests, TRH score was better than placebo in 6 (*), and placebo better than TRH in 5; none of these changes reached statistical significance.
period (T) was compared with that of the placebo period (P). A t test was done to determine the significance.
Results
Six out of seven patients completed the study. One patient developed pneumonia during the study and was withdrawn. There were no changes in the scores for tongue protrusion and speech clarity. TRH appeared effective in some items of the evaluation such as grip power and time for moving pegs, and ineffective in others such as time for 20m walk. However, statistical analysis failed to demonstrate significant improvement in any item of the evaluation (table) . Three of the patients felt subjectively better while they were receiving TRH and none while receiving placebo. They reported increased power of the fingers, improved swallowing, or less spasticity of legs. However, objective evaluation failed to confirm these subjective changes.
Two patients reported nausea after injection of TRH. Routine blood chemistry, urinalysis, and thyroid function tests revealed no abnormalities after the trials.
Discussion
Daily administration of 2 mg of TRH has been reported to improve symptoms of cerebellar ataxia.8 Yamane et 
